uua0njfv

Property	Value
?:abstract	In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (−23.3%, p < 0.0001) than in PV (−16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
?:creator	<https://research.tib.eu/covid-19/entity/Barbui%2C_Tiziano%3B_De_Stefano%2C_Valerio%3B_Alvarez-Larran%2C_Alberto%3B_Iurlo%2C_Alessandra%3B_Masciulli%2C_Arianna%3B_Carobbio%2C_Alessandra%3B_Ghirardi%2C_Arianna%3B_Ferrari%2C_Alberto%3B_Cancelli%2C_Valeria%3B_Elli%2C_Elena_Maria%3B_Andrade-Campos%2C_Marcio_Miguel%3B_Kabat%2C_Mercedes_Gasior%3B_Kiladjian%2C_Jean-Jaques%3B_Palandri%2C_Francesca%3B_Benevolo%2C_Giulia%3B_Garcia-Gutierrez%2C_Valentin%3B_Fox%2C_Maria_Laura%3B_Foncillas%2C_Maria_Angeles%3B_Morcillo%2C_Carmen_Montoya%3B_Rumi%2C_Elisa%3B_Osorio%2C_Santiago%3B_Papadopoulos%2C_Petros%3B_Bonifacio%2C_Massimiliano%3B_Cervantes%2C_Keina_Susana_Quiroz%3B_Serrano%2C_Miguel_Sagues%3B_Carreno-Tarragona%2C_Gonzalo%3B_Sobas%2C_Marta_Anna%3B_Lunghi%2C_Francesca%3B_Patriarca%2C_Andrea%3B_Elorza%2C_Bego%C3%B1a_Navas%3B_Angona%2C_Anna%3B_Mazo%2C_Elena_Magro%3B_Koschmieder%2C_Steffen%3B_Carli%2C_Giuseppe%3B_Cuevas%2C_Beatriz%3B_Hernandez-Boluda%2C_Juan_Carlos%3B_Abadia%2C_Emma_Lopez%3B_Cirici%2C_Blanca_Xicoy%3B_Guglielmelli%2C_Paola%3B_Garrote%2C_Marta%3B_Cattaneo%2C_Daniele%3B_Daffini%2C_Rosa%3B_Cavalca%2C_Fabrizio%3B_Bellosillo%2C_Beatriz%3B_Benajiba%2C_Lina%3B_Curto-Garcia%2C_Natalia%3B_Bellini%2C_Marta%3B_Betti%2C_Silvia%3B_Harrison%2C_Claire%3B_Rambaldi%2C_Alessandro%3B_Vannucchi%2C_Alessandro_Maria>
?:doi	<https://research.tib.eu/covid-19/entity/10.1038/s41408-021-00417-3>
?:doi	10.1038/s41408-021-00417-3
?:journal	Blood_Cancer_J
?:license	cc-by
?:pmc_json_files	document_parses/pmc_json/PMC7871138.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7871138>
?:pmid	<https://research.tib.eu/covid-19/entity/33563901.0>
?:pmid	33563901.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	Medline; PMC
?:title	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2021-02-04

Property

Value

?:abstract

In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (−23.3%, p < 0.0001) than in PV (−16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.

?:creator